Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Increase in Short Interest

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 3,001,500 shares, a growth of 11.2% from the October 15th total of 2,699,000 shares. Based on an average daily volume of 1,100 shares, the short-interest ratio is presently 2,728.6 days.

Innovent Biologics Trading Up 2.5 %

IVBXF opened at $4.58 on Monday. Innovent Biologics has a 52-week low of $3.83 and a 52-week high of $6.40. The company has a 50 day moving average of $5.51 and a two-hundred day moving average of $5.19.

About Innovent Biologics

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.